Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Intervalo de año de publicación
1.
Am J Dermatopathol ; 46(4): 204-211, 2024 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-38457684

RESUMEN

ABSTRACT: Mycosis fungoides (MF) has become one of the most difficult diagnostic challenges for both dermatologists and dermatopathologists because its clinical presentation and microscopic findings may mimic benign reactive processes, specifically those displaying histopathological features of interface dermatitis. The goal of our study was to prove with digital scanning and automated sample methodology through algorithmic analysis, combined with the utility of TOX marker a more precise, faster, and objective evaluation of each sample. Moreover, this would offer high levels of reproducibility with the possibility of establishing cut-off points, allowing us to distinguish between inflammatory dermatoses (ID) and MF. A retrospective longitudinal-descriptive and observational study was conducted to compare the diagnostic criteria (immunohistochemical studies of anti-TOX stain) in patients with clinical suspicion of MF by dividing them into 2 groups: samples with a positive biopsy for MF (MF group) and those with a negative biopsy, therefore diagnosed as an ID (control group). The algorithm assessed 5 selected areas with lymphocytic representative cellularity, and based on the intensity, nuclear staining was classified as 0 (negative), 1+ (weak/yellow), 2+ (moderate/orange), and 3+ (strong/scarlet red) nuclei. The results showed statistically significant differences ( P = 0.040) between the mean number of (2+) nuclei in the positive final diagnosis group (MF group) and the negative final diagnosis group (ID group).


Asunto(s)
Dermatitis , Micosis Fungoide , Neoplasias Cutáneas , Humanos , Estudios Retrospectivos , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Reproducibilidad de los Resultados , Micosis Fungoide/diagnóstico , Micosis Fungoide/patología , Linfocitos/patología , Dermatitis/patología
2.
Respirar (Ciudad Autón. B. Aires) ; 15(3): [157-167], sept. 2023.
Artículo en Español | LILACS, UNISALUD, BINACIS | ID: biblio-1510520

RESUMEN

Introducción: la fibrosis pulmonar idiopática (FPI) es una enfermedad progresiva y cró-nica con muy mal pronóstico. Actualmente, existen dos fármacos para esta patología. El propósito de nuestro estudio es evaluar los efectos del tratamiento en los pacientes de una consulta en vida real.


Introduction: idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with a very poor prognosis. Two drugs are currently available for this disease. The purpo-se of our study is to evaluate the effects of treatment in patients in a real-life practice.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Disnea , Fibrosis Pulmonar Idiopática/tratamiento farmacológico , Antifibróticos/uso terapéutico , Pruebas de Función Respiratoria , Eficacia , Tolerancia a Medicamentos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA